Supernus, Inc. (NASDAQ: SUPN) is a Healthcare company (Drug Manufacturers - Specialty & Generic) with a market capitalization of $6.0B. The Maz Rating grades it against the other companies in its sector.
Supernus, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $29.04, Supernus, Inc. trades at 8.0x trailing earnings and 4.4x sales, with an EV/EBITDA of 11.0. Over the last twelve months it generated about $1.4B of revenue and $758M of net income. It runs a gross margin of 85.2%, an operating margin of 43.7% and a net margin of 32.8%. It shows return on equity of -352.9%, return on invested capital of 95.4% and a free cash flow yield of 0.5%. On the balance sheet: a debt-to-equity ratio of -8.35 and a current ratio of 0.61. Over the past 52 weeks the share price ranged from $25.92 to $43.20, with a beta of 0.52.
Supernus, Inc. pays a dividend yielding 27.93%.
12 Wall Street analyst ratings cover the stock: 10 Buy and 2 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Supernus, Inc. is a diversified biopharmaceutical company focused on developing and commercializing treatments for central nervous system (CNS) diseases. Its portfolio of 11 marketed products spans opioid use disorder, psychiatry, and neurology, and includes SUBLOCADE, a long-acting injectable buprenorphine for opioid use disorder, along with sublingual OUD treatments; Qelbree, a non-stimulant treatment for attention-deficit hyperactivity disorder (ADHD); GOCOVRI for dyskinesia in Parkinson’s disease patients receiving levodopa-based therapy; ONAPGO for motor fluctuations in advanced Parkinson’s disease; ZURZUVAE for postpartum depression; and treatments for epilepsy, migraine, cervical dystonia, and chronic sialorrhea, including Oxtellar XR, Trokendi XR, APOKYN, and MYOBLOC. The company also advances a pipeline of novel CNS product candidates. Its products are sold primarily in the United States, with additional markets including Canada, Australia, France, and Germany. The company was formed through the November 2026 merger of Supernus Pharmaceuticals, Inc. and Indivior Pharmaceuticals, Inc., and is headquartered in Rockville, Maryland.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
It depends on the standard you follow. As of September 2026, Supernus, Inc. (SUPN) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 11.5% / 30% · (Cash+Inv) / Mkt Cap (36m) 7.81% / 30% · Interest income / Revenue 1.12% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 11.5% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 7.17% / 33% · Receivables / Mkt Cap (36m) 6.73% / 49% · Interest income / Revenue 1.12% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 11.5% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 7.17% / 33.33% · Receivables / Mkt Cap (24m) 6.73% / 33.33% · Interest income / Revenue 1.12% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 36.4% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 18.1% / 33.33% · Receivables / Avg Assets (4Q) 22.4% / 33.33% · Interest income / Revenue 1.12% / 5% | Fail |
| FTSE | Debt / Total Assets 36.6% / 33.33% · (Cash+ST Inv) / Total Assets 22.9% / 33.33% · (Cash+Recv) / Total Assets 44.4% / 33.33% · Interest income / Revenue 1.12% / 5% | Fail |
It depends on the standard you follow. As of September 2026, Supernus, Inc. (SUPN) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
Yes. Supernus, Inc. is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
About 1.12% of each dividend: Supernus, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.